Postoperative mortality · adults undergoing pancreatoduodenectomy (mainly for pancreatic cancer)
Pancreaticojejunostomy showed no clear difference in postoperative mortality compared with pancreatogastrostomy after pancreatoduodectomy (moderate certainty).
1 finding from 1 review
Early neonatal mortality · neonates with possible serious bacterial infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Early neonatal mortality · neonates with sepsis
Comparison 1: community‐based antibiotic delivery probably leads to lower early neonatal mortality compared with standard care (moderate certainty).
1 finding from 1 review
Early neonatal mortality · neonates with fast breathing alone
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Early neonatal mortality · developing countries
It is very uncertain whether community health educational interventions changes early neonatal mortality compared with control (very low certainty).
2 findings from 1 review
All‐cause mortality during hospital stay and all‐cause mortality at 1 year · people with endocarditis caused by Staphylococcus aureus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality: all cancers · Participants in non experimental cohort studies on selenium and cancer
It is very uncertain whether highest changes cancer mortality risk No. of participants: 183,863 (7 observational… compared with lowest selenium exposure (very low certainty).
1 finding from 1 review
Sepsis‐specific mortality · neonates with sepsis
Comparison 1: community‐based antibiotic delivery showed no clear difference in sepsis‐specific mortality compared with standard care (low certainty).
1 finding from 1 review
Overall mortality (end of · patients with venous thromboembolism.
LMWH showed no clear difference in overall mortality (end of compared with UFH (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality (after 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention showed no clear difference in mortality (after 3 years) (moderate certainty).
1 finding from 1 review
All‐cause mortality Study duration range 12‐96 months Omega‐6 dose range 1.5%‐24.5% E · adults with or without existing CVD
Higher showed no clear difference in all‐cause mortality Study duration range 12‐96 months Omega‐6 dose… compared with lower omega‐6: primary outcomes (low certainty).
1 finding from 1 review
Cardiovascular mortality · adults with or without existing CVD
It is very uncertain whether higher changes cardiovascular mortality Study duration range 24‐96 months Omega‐6… compared with lower omega‐6: primary outcomes (very low certainty).
1 finding from 1 review
Intervention not reported
Diabetes‐related mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Diabetes‐related mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Diabetes‐related mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Diabetes‐related mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Diabetes‐related mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause in‐hospital mortality by 36 weeks' postmenstrual ageUnit: number of infants with event · preterm infants with respiratory dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment‐related mortality
Pembrolizumab showed no clear difference in treatment‐related mortality compared with chemotherapy (low certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related mortality · people with non‐rhabdomyosarcoma soft tissue sarcoma
1 finding from 1 review